Ketorolac and pregabalin for estrogen receptor positive breast cancer before surgery
Treatments studied
Part of Cancer, Hormones & metabolism, Skin clinical trials.
This trial tests whether two medications, ketorolac (a pain reliever) and pregabalin (a nerve pain drug), can help treat estrogen receptor (ER) positive breast cancer when taken before surgery. It may offer better pain control and possibly improve cancer outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 70.
- Your breast cancer is estrogen receptor (ER) positive and at least 1.5 cm in size.
- Your cancer is stage I, II, or III (has not spread to distant organs).
- You are scheduled for breast cancer surgery and willing to take omeprazole (a stomach acid reducer).
- You have no history of bleeding problems, stomach ulcers, or use of NSAID pain relievers or pregabalin recently.
- You are not pregnant, do not have certain chronic illnesses (like severe asthma, heart failure, or autoimmune disease), and are willing to use effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking letrozole, a hormone-blocking pill, before surgery can help shrink estrogen-positive breast cancer. It is for women who have gone through menopause and have early-stage cancer that has spread to nearby lymph nodes.
This trial tests a combination of targeted therapies and chemotherapy given before surgery for women with a specific type of breast cancer that is both ER-positive and HER2-positive. The goal is to see if this treatment can shrink tumors and improve outcomes.
This trial combines a short course of radiation before surgery with two oral medications (abemaciclib and letrozole) to treat early-stage, hormone-sensitive breast cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a new drug combination given before surgery for early-stage, hormone receptor-positive breast cancer. It aims to see if this approach can improve outcomes for patients with high-risk features.
This study tests different treatment plans given before surgery for early breast cancer that is both hormone receptor-positive and HER2-positive. The goal is to see which treatment is more effective and to tailor it to each patient.
This trial compares two combination treatment plans given before breast surgery (neoadjuvant therapy) for ER-positive and HER2-positive stage II–III breast cancer. It aims to see which plan works better to shrink the tumor and improve outcomes.
Hear when a new Early-stage Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.